News headlines about IGI Laboratories (NYSE:IG) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IGI Laboratories earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.3659513758203 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
IGI Laboratories (NYSE IG) remained flat at $7.68 during mid-day trading on Thursday. IGI Laboratories has a one year low of $4.75 and a one year high of $12.05. The stock’s 50-day moving average price is $7.71 and its 200-day moving average price is $7.24.
About IGI Laboratories
IGI Laboratories, Inc is a specialty generic pharmaceutical company. Under its IGI label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.
Receive News & Ratings for IGI Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGI Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.